Cardiac Surgery-associated Acute Kidney Injury
Conditions
Keywords
CSA-AKI, Cardiac surgery, Cardiopulmonary bypass
Brief summary
Researchers are looking for a better way to treat and prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in people who undergo heart surgeries. CSA-AKI is a common complication in people undergoing heart surgeries, where the kidneys stop working properly. CSA-AKI risk factors include older age and alongside diseases such as kidney disease and diabetes. Longer time with heart-lung machine during heart surgeries also increases the occurrence of CSA-AKI. In this study, researchers want to better understand how CSA-AKI develops (also known as the mechanisms involved in the development of CSA-AKI) in people under heart surgeries, the presence of certain biomarkers in the body, especially with a focus on the early hours and days after the surgery. (A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.) These biomarkers will be compared in participants who develop CSA-AKI within a week after heart surgery with the participants who do not develop CSA-AKI. The relationship with biomarkers will be determined by examining participants' blood and urine samples before and after surgery. This may help researchers better understand CSA-AKI, identify potential treatment targets and develop possible treatments to prevent CSA-AKI. Participants in this study will be people who have heart surgery already scheduled by their own doctors and have a risk of developing CSA-AKI. Participants will not receive any treatment as part of this study. They will undergo the heart surgery and related medical processes as per their normal medical treatment and management. Each participant will be in the study for up to 2 months. During the study, the doctors and their study team will: * collect participants' blood and urine samples before and after surgery * assess participants' medical records and test reports during hospitalization * monitor overall health of the participants throughout the study
Interventions
No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.
Sponsors
Bayer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant must be at least 18 years of age at the time of signing the informed consent form (ICF). * Participants who are scheduled for hospital admission for any of the following cardiovascular surgery interventions, alone or in combination, involving cardiopulmonary bypass (CPB): * Aortic, mitral, or tricuspid valve surgery (repair or replacement) * Aortic surgery * ≥3 coronary artery bypass grafts * Participant with: chronic kidney disease (CKD): 30 ≤ estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73 m\^2
Exclusion criteria
* Emergency surgery situation * Anemia - hemoglobin \<10 g/dL * Clinical signs of systemic infection or other infection requiring anti-infective treatment (viral, bacterial, fungal, parasitic; single-dose prophylaxis allowed) * Systemic immunosuppressive or anti-inflammatory treatment including corticosteroids \>10 mg prednisolone equivalent/day * Any anti-cancer treatment within 3 months (e.g. immunotherapy, chemotherapy, radiotherapy) * Major surgery within 2 months * AKI within the last month * Prior renal transplants or RRT * Planned use of contrast media within 5 days prior to surgery or during surgery * Patient included in an interventional clinical trial involving a pharmacological intervention * Any reason that would make participation unadvisable, at the discretion of the investigator. * Autoimmune disorders such as anti-glomerular basement membrane (anti-GBM) diseases, systemic lupus erythematosus, chronic rheumatic heart diseases, acute rheumatic heart pericarditis, endocarditis, myocarditis, rheumatic mitral valve diseases, rheumatic aortic valve diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with CSA-AKI until Day 3 post-surgery | Up to 3 days post surgery | CSA-AKI: cardiac surgery-associated acute kidney injury |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observed values of pre-defined biomarkers overall and by CSA-AKI outcome | Up to 7 days post surgery | Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury |
| Change from baseline of pre-defined biomarkers overall and by CSA-AKI outcome | Up to 7 days post surgery | Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury |
| Ratio to baseline of pre-defined biomarkers overall and by CSA-AKI outcome | Up to 7 days post surgery | Non-genetic biomarkers will be investigated from blood, plasma, and urine collected in this study. CSA-AKI: cardiac surgery-associated acute kidney injury |
Countries
Germany, United Kingdom
Contacts
CONTACTBayer Clinical Trials Contact
Outcome results
None listed